Marc Larkins
@Johnson & Johnson
Latest period2024 - Q3ReportedManaged Assets$427.326MTotal holdings20
Assets growth rate6.66%Assets growth rate (2-Q avg)-42.13%Continuous growth in asset value1 quarters
Portfolio positions
This chart displays the top 10 holdings in Johnson & Johnson's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 20 positions.
Assets under management
The assets under management (AUM) of Johnson & Johnson over the past 10 years (40 quarters) show continuous growth in total asset value over the last 1 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 427.326M in assets, with a quarterly growth rate of 6.66% and a 2-quarter average growth rate of -42.13%. The portfolio is managed by Marc Larkins, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
PTGXProtagonist Therapeutics Inc.
| 25.8% | $110.213M 2.449M shares@ $45.0 avg price | |
RAPPRapport Therapeutics, Inc.
| 11.98% | $51.16M 2.498M shares@ $20.48 avg price | |
LEGNLegend Biotech Corporation
| 9.29% | $39.695M 814,586 shares@ $48.74 avg price | |
CTNMContineum Therapeutics Inc.
| 8.87% | $37.881M 1.979M shares@ $19.14 avg price | |
CVRXCvrx, Inc.
| 8.46% | $36.151M 4.103M shares@ $8.81 avg price | |
NBTXNanobiotix S.a.
| 7.57% | $32.337M 5.624M shares@ $5.75 avg price | |
PRCTProcept Biorobotics Corporation
| 6.72% | $28.678M 357,939 shares@ $80.13 avg price | |
MGTXMeiragtx Holdings Plc
| 6.49% | $27.693M 6.641M shares@ $4.18 avg price | |
NMRANeumora Therapeutics, Inc.
| 5.72% | $24.431M 1.849M shares@ $13.21 avg price | |
XNCRXencor, Inc.
| 3.53% | $15.044M 748,062 shares@ $20.12 avg price |